Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Structure Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

About Structure Therapeutics Inc.

Structure Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics targeting GPCRs for chronic diseases. Its pipeline includes candidates for obesity, diabetes, pulmonary fibrosis, and other metabolic and inflammatory conditions. Leveraging structure-based drug discovery and computational chemistry, the company aims to create accessible, scalable, and effective treatments that overcome limitations of biologics and peptides.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Structure Therapeutics Inc.

1
1
Structure Therapeutics Inc. Structure Therapeutics Reports $75.9 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Structure Therapeutics Inc. Structure Therapeutics Reports $141.2 Million Net Loss and Business Update in Annual 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Structure Therapeutics Inc. Structure Therapeutics Reports $65.7M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Structure Therapeutics Inc. Structure Therapeutics Reports $61.7 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Structure Therapeutics Inc. Structure Therapeutics Reports $46.8 Million Net Loss in Q1 2025, Highlights Clinical Advancements

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Structure Therapeutics Inc. Structure Therapeutics Reports $33.98M Net Loss, Increases Research and Development Expenses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments